HOME >> MEDICINE >> NEWS
New class of targeted cancer drugs shows promise in slowing progression of recurrent prostate cancer

paradigm for cancer treatment, and is a promising area of research. This study must be viewed cautiously, however, as we are comparing statistics from historical control groups.

Pertuzumab is a single-agent antibody designed to bind to the HER2 receptor and inhibit the ability of HER2 to pair with other HER family members (HER1, HER2, HER3 and HER4). If the pairing process (called dimerization) is not interrupted, the binding of these growth factors activates an intracellular signaling pathway that leads to tumor proliferation.

While other drugs such as docetaxel have shown to benefit men with advanced prostate cancer, no other second-line therapy (a treatment given when an initial treatment (first-line therapy) does not work or stops working) to date has shown to prolong survival.

Previous research published by cancer researchers at Cedars-Sinai and other institutions has shown that pertuzumab affects the growth of several other types of cancers, including breast, ovarian and lung cancer, and that the drug may also prolong survival for patients with advanced ovarian cancer.

In the current study, the pertuzumab was well-tolerated but no objective tumor shrinkages were observed. No decline in PSA (prostate-specific antigen; a tumor marker) levels was detected in patients during the study. According to the researchers, this study raises a question long debated in prostate cancer literature: what should clinical outcome standards or end point be the for studies involving patients with advanced, intractable prostate cancer who have limited treatment options.

The next step for researchers is to test the pertuzumab on a larger group of patients in a randomized fashion, and to analyze data that is not retrospective.

Prostate cancer is the most common type of cancer found in American men, other than skin cancer and is the second leading cause of cancer death in men. The American Cancer Society estim
'"/>

Contact: Simi Singer
simi.singer@cshs.org
310-423-4768
Cedars-Sinai Medical Center
16-Feb-2007


Page: 1 2 3

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. Early-morning Friday classes may prevent students from getting sloppy on thirsty Thursdays
3. Panel offers guidelines on skin reactions to new class of cancer drugs
4. UK researchers find new class of nontoxic cancer treatments
5. New class of HIV drug attacks previously untargeted enzyme
6. Sleep disturbances affect classroom performance
7. Simple classification can help define and predict limb-threatening diabetic infections
8. World-class Biomedical Research Center to be in West London
9. A new way of classifying addictive drugs
10. Phys ed class more effective when theres more talking
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... ... March 30, 2017 , ... AudioEducator, a leader in training ... Readmissions Through Discharge Planning ” with noted expert Sue Dill Calloway, RN, MSN, ... strategies to prevent readmissions in light of the most recent programs at the ...
(Date:3/29/2017)... Utah (PRWEB) , ... March 29, 2017 , ... During ... event to provide free screening colonoscopies to eligible individuals in the local community. ... the U.S., but regular screenings can detect colon cancer while it is small, confined ...
(Date:3/29/2017)... ... , ... In the United States alone, up to 36% of primary brain ... metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors are known to ... treatment options, the San Diego Gamma Knife Center offers a precision-medicine based ...
(Date:3/29/2017)... ... 2017 , ... Full Contact K9, an Atlanta-based dog services provider, has recently ... assists dog owners in creating legally-enforceable pet trusts for their canine companions. , ... to protect their new companion. Says Evan Dunbar, CEO of Full Contact K9, “When ...
(Date:3/29/2017)... Baltimore, MD (PRWEB) , ... March 30, 2017 , ... ... , Charm City Run has announced that Mercy Medical Center will serve as the ... in the Mid-Atlantic region. On Sunday, June 25, 2017, thousands of women will walk ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Research and Markets has announced the addition of the ... to their offering. ... The global orthopedic navigation system market is ... population prone to orthopedic diseases is a key contributing factor ... period. Osteoarthritis and osteoporosis are most common disorders in the ...
(Date:3/29/2017)... , Mar 29, 2017  Providence Medical Technology, ... the addition of two industry veterans to the ... joined the company to lead Global Marketing, and ... Together, Mr. Lynch and Mr. Scott have over ... Mr. Lynch joins the company with over ...
(Date:3/29/2017)... March 29, 2017  The leader in accelerated orthodontics, ... Sam Daher , Manal Ibrahim , ... Couchat will be the featured microlecture presenters at the ... Association of Orthodontists (AAO) Annual Session, April 21-25, 2017. ... microlectures beginning daily at 11:20 a.m. On the opening ...
Breaking Medicine Technology:
Cached News: